跳至主要内容
临床试验/NCT03015831
NCT03015831终止3 期

Effect of Low Dose ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients

Jordan Collaborating Cardiology Group3 个研究点 分布在 1 个国家目标入组 254 人开始时间: 2017年10月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
入组人数
254
试验地点
3
主要终点
Atrial fibrillation

研究概览

简要总结

The prior End-AF study by the same group showed that 1 mg of colchicine didn't decrease the incidence of AF after cardiac surgery. The current study, End-AF Low Dose Study, will test 0.5 mg colchicine vs. placebo in preventing AF after cardiac surgery.

详细描述

AF after cardiac surgery leads to excess mortality and morbidity. Colchicine was used in several studies to lower the incidence AF but the results were generally disappointing. There was no benefit in reducing AF and there was a high incidence of GI side effects especially diarrhea, often leading to stopping the medication. However, a recently published meta-analysis showed that colchicine reduced AF, but again warned of the high incidence of GI side effects. The maintenance dose of colchicine used in these studies was 1 mg daily it is hypothesized that low dose colchicine (0.5 not 1 mg colchicine) might lower AF after cardiac surgery without the prohibitive GI side effects Patients will be randomized to colchicine vs. placebo started the day before surgery and continued until hospital discharge.

The primary efficacy endpoint will be the incidence of AF. The primary safety endpoint will be the GI side effects

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients aged 18 years or above undergoing elective cardiac surgery.
  • Sinus rhythm and no previous AF
  • Agreed to sign informed consent.

排除标准

  • Known severe liver disease or current transaminases >1.5 times the upper normal limit
  • Current serum creatinine >2.5 mg/dL
  • Known myopathy or elevated baseline preoperative creatine kinase
  • Known blood dyscrasias or significant gastrointestinal disease
  • Pregnant and lactating women
  • Known hypersensitivity to colchicine
  • Current treatment with colchicine for any indications
  • Emergency surgery

研究组 & 干预措施

Colchicine

Active Comparator

Intervention by administering an active copmarator of 1 mg colchicine one day pre op and 0.5 mg daily after surgery until discharge

干预措施: Colchicine (Drug)

Placebo Oral Tablet

Placebo Comparator

Identical tablet (placebo) administered in a similar way as that in the active comparator arm

干预措施: Placebo Oral Tablet (Drug)

结局指标

主要结局

Atrial fibrillation

时间窗: Through study completion, an average of 1 week

AF documented by EKG

次要结局

  • Side effects of colchicine(Through study completion, an average of 1 week)

研究者

发起方
Jordan Collaborating Cardiology Group
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验